Ashley Wozniak
Acute Care · Livonia, MINPI 1770006637
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,001 of the $26,392 with a category attached, or 68.2%. 20 manufacturers reported payments, led by Vifor Pharma, Inc. at 52.0% of the total. Reporting peaked in 2023 at $9,185 and has fallen 91.1% since, to $822 in 2025. Among acute care clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $90.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$14K
- Fresenius USA Marketing, Inc.$6K
- Bayer$3K
- Akebia Therapeutics Inc$723
- Travere Therapeutics, Inc.$463
- AstraZeneca$421
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$18,00168%
- Travel & lodging$2,76810%
- Food & beverage$5,50721%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 86 | $13,721 |
| Fresenius USA Marketing, Inc. | 25 | $6,447 |
| Bayer | 31 | $3,137 |
| Akebia Therapeutics Inc | 45 | $723 |
| Travere Therapeutics, Inc. | 23 | $463 |
| AstraZeneca(2 entities) | 15 | $421 |
| Aurinia Pharma U.S., Inc. | 11 | $291 |
| Calliditas Therapeutics US Inc. | 14 | $252 |
| Novartis | 6 | $192 |
| Ardelyx, Inc. | 6 | $121 |
| Boehringer Ingelheim | 6 | $120 |
| OPKO Pharmaceuticals, LLC | 6 | $115 |
| ANI Pharmaceuticals, Inc. | 4 | $80 |
| GSK | 4 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| Mallinckrodt Hospital Products Inc. | 3 | $51 |
| Amgen | 2 | $39 |
| Sanofi | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,392 in reported general payments places this provider in the 95th percentile of 567 acute care providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 33 | $159,515 |
| XphozahTenapanor Hcl | 35 | $111,067 |
| Lanthanum Carbonate | 19 | $37,667 |
| EliquisApixaban | 26 | $22,619 |
| Sevelamer Carbonate | 144 | $20,572 |
| VeltassaPatiromer Calcium Sorbitex | 28 | $18,560 |
| JardianceEmpagliflozin | 17 | $17,619 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $16,749 |
| KerendiaFinerenone | 14 | $12,849 |
| RenvelaSevelamer Carbonate | 11 | $10,150 |
| Calcium Acetate | 40 | $4,764 |
| Midodrine Hcl | 31 | $2,060 |
| Nifedipine ErNifedipine | 48 | $1,559 |
| Hydralazine Hcl | 75 | $996 |
| Carvedilol | 91 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $6,447 | $159,51533 claims |
| Boehringer IngelheimJardiance | $120 | $17,61917 claims |
| AstraZenecaLokelma | $421 | $16,74926 claims |
| BayerKerendia | $3,137 | $12,84914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 acute care providers in Michigan.
Other acute care in Livonia
- Janet WymanDetroit$103K
- Stephanie Mellon ReppenDetroit$57K
- Julia BriggsBirch Run$16K
- Candise LovePort Huron$14K
- Janette GuertinPort Huron$14K
- Gregory AliNovi$13K
- Andrew PalmerLansing$9K
- Angela BrennanDearborn Heights$7K
- Jennifer RutzenLansing$7K
- Holly WuestMonroe$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.